FDA approves first veterinary amlodipine for feline hypertension: full analysis

The FDA has approved Amodip, a chewable amlodipine besylate tablet from Ceva Santé Animale, for the control of systemic hypertension in cats, marking the first FDA-approved veterinary amlodipine product in the U.S. The approval, announced April 29, 2026, gives veterinarians a feline-specific version of a drug that has been widely used off-label for years and is already considered a first-line antihypertensive in cats by major consensus guidance. (fda.gov)

That matters because systemic hypertension in cats is rarely a niche problem in practice. FDA and academic guidance both note that it’s commonly associated with chronic kidney disease and also seen with hyperthyroidism, heart disease, primary hyperaldosteronism, or no clearly identified underlying cause. Left untreated, high blood pressure can damage the eyes, kidneys, heart, brain, and central nervous system, making early detection and sustained control clinically important, especially in older feline patients. (fda.gov)

The approval also closes a long-standing regulatory gap. Before this week, the only FDA-approved drug specifically indicated to control high blood pressure in cats was Semintra, a telmisartan oral solution approved in 2018. By contrast, amlodipine has had deeper support in the feline hypertension literature for decades. The ACVIM consensus statement describes amlodipine besylate as the first choice for antihypertensive treatment in cats, and Cornell’s Feline Health Center similarly identifies it as the general first-line medication. (fda.gov)

FDA’s label summary says Amodip is given daily at the standard dose for the first 14 days, with a possible dose increase afterward if response is inadequate. The agency said cats weighing less than 2.5 kg can’t be accurately dosed with the product. Veterinarians are advised to monitor blood pressure regularly and check kidney and liver values early in treatment, while pet parents should be counseled to watch for decreased appetite, vomiting, and diarrhea. Amodip is prescription-only, and the sponsor is Ceva Santé Animale of France. (fda.gov)

The clinical backdrop for the approval is well established. Earlier published work, including a randomized placebo-controlled trial of a chewable amlodipine formulation in client-owned cats, described an unmet need for a cat-specific formulation and supported the drug’s antihypertensive effect. The ACVIM consensus statement cites typical systolic blood pressure reductions of roughly 28 to 55 mm Hg in hypertensive to severely hypertensive cats, and notes that cats with systolic blood pressure above 200 mm Hg may benefit from a higher starting dose than cats with less severe disease. (pmc.ncbi.nlm.nih.gov)

Industry reaction was limited in public view at the time of writing; Ceva’s public newsroom did not appear to show a separate approval announcement in the search results reviewed. Still, the broader expert position is clear. Consensus and teaching resources continue to frame amlodipine as the preferred first-line agent for many feline hypertension cases, particularly because of its established efficacy and because ACE inhibitors alone generally don’t lower systolic pressure enough in most cats. (ceva.com)

Why it matters: For veterinary teams, this is less about introducing a novel mechanism than about upgrading the standard toolkit. A labeled veterinary amlodipine product may improve dosing consistency, client communication, and confidence around safety, quality, and administration compared with splitting human tablets or using compounded preparations. It also gives practices another FDA-approved option in a category where treatment decisions often intersect with CKD, proteinuria, hyperthyroidism, and target-organ damage, all of which require close follow-up and individualized monitoring. (fda.gov)

What to watch: The near-term questions are commercial and clinical: when distribution broadens, whether the chewable format improves adherence in real-world use, and how practices position Amodip relative to telmisartan, combination therapy, and existing off-label amlodipine workflows. The approval may not change first-line thinking overnight, but it does give that thinking a formal FDA-backed product to attach to. (fda.gov)